XTL Biopharmaceuticals Extraordinary General Meetings Postponed Until October 10, 2008
October 02 2008 - 10:37AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., Oct. 2 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced
that its Extraordinary General Meetings ("EGMs") were postponed
until October 10, 2008 in accordance with its articles of
association due to the absence of a quorum. The postponed EGMs will
take place at the offices of Kantor & Co. Law Offices, 14 Abba
Hillel Silver Road, Oz House, 12th Floor, Ramat Gan, Israel at 3:00
p.m. Israel time, and 5:30 p.m. Israel time, respectively, on
October 10, 2008. Any proxy votes received at any time up to 48
hours prior to the postponed EGMs will be included in the total
votes counted for the EGMs. Those shareholders who have a valid
"proof of ownership" in Israel or a letter of representation from
Computershare, the Company's United Kingdom registrars, and attend
the meeting in person will also be permitted to vote. ABOUT XTL
BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is
engaged in the development of therapeutics for the treatment of
diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a
serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain, which is currently in a Phase 2b
study. XTL has out-licensed its novel pre-clinical HCV small
molecule inhibitor program. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv
Stock Exchanges (NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL
Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive
Officer, XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024